Hacker News new | ask | show | jobs
by 9872 3927 days ago
Companies publish plenty of research. And unlike universities, they actually make products people can use, which is even better.
2 comments

> unlike universities, they actually make products people can use

Universities also produce lots of things that people actually use directly in the form of Free or Open Source Software. BSD, GNU, Mach, etc. Many of the architects of the Internet were working at universities too. It's not fair to dismiss them as you did.

And some companies publish plenty of research. Microsoft is very impressive. Google good but less. Apple not so much.

Yes, they do publish plenty of research, and thanks to the Bayh-Doyle act they make a lot of money off publicically funded entities too. Those great discoveries are patented, and those licensing fees are making products expensive.

I'm not bashing the act; government wasn't getting the job done.

I would rather see something like a prize system in tech, and medical discoveries. For instance, we need a cure for a certain disease. The government could offer, say a 1 billion dollar prize, to the first company that solves the problem.

The discovery would then be required to open sourced to U.S. companies? Hell, it might prevent some companies from relocating overseas to avoid taxes? So instead of outrageous drug prices, generic drug companies would bring the price down due to competition?

(a little off topic, but relevant? Maybe not relevant towards gadgets, but relative to expensive medical cures?)

http://www.ucop.edu/ott/faculty/bayh.html

The government could offer, say a 1 billion dollar prize, to the first company that solves the problem.

There are a number of challenges with the "prize" system. Who judges whether or not an invention qualifies for the prize? Things aren't black and white in biotech. If you're drug cures a disease but has bad side effects, does that deserve a prize? What if you don't cure the disease, but you massively reduce the burden of the disease. Do you deserve a prize?

Second, the prizes would have to be much larger than $1B. Gilead (who sells the hepatitis C cure Sovaldi and Harvoni) sold $5B worth of the drugs in Q2 of this year. Their margins are likely >50%. Even relatively small drug have NPVs of several billion.

The other issue with the prize system is it makes the 2nd to market impossible. It's a disincentive to competition. Under the old system you could have two, similar drugs sold and they battle it out for market share. Even if you split the market it can be profitable. Under the prize system, if you're 2nd to market, well, tough, you get absolutely nothing. A lot of drug development is incremental. Lipitor was the 5th statin to market (and the best out of all of them). With the prize system you'd get one drug and that's it.